Core Viewpoint - The report highlights the significant growth driven by technology in certain sectors, while also noting the substantial losses due to cyclical downturns in others [1] Performance Growth Highlights - **Zhongwei Company (688012)**: Expected net profit between 208 million to 218 million yuan, a year-on-year increase of 28.74% to 34.93%, driven by increased recognition of plasma etching equipment and a surge in market demand [5] - **Lianchuang Optoelectronics (600363)**: Expected net profit between 43.5 million to 53.2 million yuan, a year-on-year increase of 80.36% to 120.57%, attributed to significant growth in laser business and improved profitability in traditional sectors [6] - **Ruixin Microelectronics (603893)**: Expected net profit between 102.3 million to 110.3 million yuan, a year-on-year increase of 71.97% to 85.42%, driven by rapid growth in the AIoT market and recognition of new AI technology [7] - **Sangfor Health (688336)**: Expected net profit around 290 million yuan, a year-on-year increase of approximately 311.35%, due to a significant collaboration with Pfizer and advancements in clinical research [8] - **Pulite (002324)**: Expected net profit growth of 155.76% to 194.73%, driven by the demand for high polymer materials in the automotive lightweight trend [9] - **Tonghua Dongbao (600867)**: Expected net profit around 124.21 million yuan, turning from loss to profit, driven by market share gains in insulin products [10] - **Suotong Development (603612)**: Expected net profit between 73 million to 85 million yuan, a year-on-year increase of 167.98% to 212.03%, due to rising prices and demand in the prebaked anode industry [11] Major Performance Declines - **China Shipbuilding Technology (600072)**: Expected net loss between -260 million to -340 million yuan, a year-on-year decline of over 24 times, due to cyclical downturns in shipbuilding and high material costs [12] - **Silver Nonferrous Metals (601212)**: Expected net loss between -45 million to -67.5 million yuan, transitioning from profit to loss due to legal disputes affecting financial performance [13] - **China Metallurgical Group (601618)**: Expected net profit between 130 million to 160 million yuan, a year-on-year decline of 76.28% to 80.73%, impacted by the downturn in the construction industry [14] - **Jindi Group (600383)**: Expected net loss between -1.11 billion to -1.35 billion yuan, with increased losses due to declining sales and inventory impairments [15] - **Jianfa Co. (600153)**: Expected net loss between -1 billion to -520 million yuan, transitioning from profit to loss due to increased impairments in real estate [16] Industry Trend Analysis - **Technology and Innovation-Driven Sectors**: Companies in semiconductor equipment, laser military applications, and innovative pharmaceuticals are experiencing rapid growth due to high demand in AIoT, national defense, and biomedicine [23] - **Traditional Cyclical Industries**: Sectors like coal and engineering machinery are facing significant adjustments due to demand shortages and price declines, leading to widespread performance pressures [24] - **Pharmaceutical Industry Disparities**: Innovative drugs are seeing explosive growth through external licensing, while traditional formulations and raw materials are significantly impacted by procurement policies [24] - **External Environment Uncertainties**: Factors such as international trade tensions and regulatory changes are significantly affecting corporate performance, necessitating enhanced risk management [24] - **Asset Quality Risks**: Many companies are reporting substantial asset impairment provisions, indicating potential inefficiencies in previous investments [24]

1月27日，华海药业跌5.19%，截至发稿，报16.25元/股，成交2.66亿元，换手率1.07%，总市值243.30亿 元。 截至发稿，罗文杰累计任职时间12年284天，现任基金资产总规模1713.58亿元，任职期间最佳基金回报 186.88%， 任职期间最差基金回报-47.6%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 数据显示，南方基金旗下1只基金位居华海药业十大流通股东。南方中证500ETF（510500）三季度减持 25.01万股，持有股数1316.75万股，占流通股的比例为0.88%。根据测算，今日浮亏损失约1171.91万 元。 南方中证500ETF（510500）成立日期2013年2月6日，最新规模1446.9亿。今年以来收益13.9 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. announced a significant decrease in its 2025 annual net profit, projecting a range of 224 million to 335 million yuan, which represents a decline of approximately 70% to 80% compared to the previous year [4][7]. Group 1: Financial Performance - The company expects its net profit attributable to shareholders for 2025 to be between 224 million and 335 million yuan, a decrease of approximately 78.4 million to 89.5 million yuan from the previous year [4][7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 113 million and 226 million yuan, reflecting a decline of about 90.3 million to 101.6 million yuan year-on-year [4][7]. - The previous year's net profit was reported at 1.119 billion yuan, with a per-share earnings of 0.77 yuan [8]. Group 2: Reasons for Performance Change - The decline in profit is attributed to intensified competition and price pressure in the domestic formulation business, leading to a decrease in sales revenue [8]. - The raw material pharmaceutical industry is facing overcapacity and price pressures, with new product development not meeting expectations, further impacting sales revenue [8]. - Increased investment in the research and development of innovative biological drugs has also contributed to the rise in expenses [8]. Group 3: Convertible Bond Price Adjustment - The company’s board decided not to adjust the conversion price of the "Huahai Convertible Bonds" downwards, despite the stock price falling below 80% of the conversion price for at least 15 trading days within a 30-day period [14][24]. - The current conversion price is set at 33.06 yuan per share, with the initial conversion price being 34.66 yuan per share [15][24]. - The board will reassess the situation after March 27, 2026, should the conditions for a downward adjustment be met again [14][24].

证券日报网讯 1月26日，华海药业发布2025年度业绩预减公告称，公司2025年度实现归属于上市公司股 东的净利润预计在22，400万元至33，500万元之间，与上年同期相比将减少约78，398万元到89，498万 元，同比降低约70%到80%。 （编辑 袁冠琳） ...

Performance Reports - Company Kexin New Energy (300731.SZ) expects a net profit of 30 million to 40 million yuan in 2025, representing a year-on-year growth of 73.62% to 131.49% due to the promotion of new battery applications [2] - Company AVIC Chengfei (302132.SZ) anticipates a net profit of 3.4 billion to 3.6 billion yuan in 2025, reflecting a growth of 5.47% to 11.67% compared to the previous year [2] - Company ST Jinggu (600265.SH) projects a revenue of 175 million to 205 million yuan in 2025, with a net loss of 265 million to 215 million yuan, potentially triggering delisting risk [2] - Company Yijiahe (603666.SH) expects a net loss of 35 million to 24 million yuan in 2025, an improvement from a loss of 218 million yuan in the previous year [3] - Company Guoke Micro (300672.SZ) forecasts a net loss of 180 million to 250 million yuan in 2025, a significant decline from a profit of 97.15 million yuan in the previous year [3] - Company Xinbeiyang (002376.SZ) anticipates a net profit of 70 million to 80 million yuan in 2025, a year-on-year increase of 44% to 65% driven by growth in smart logistics equipment [3] - Company Tianyue Advanced (688234.SH) expects a net loss of 185 million to 225 million yuan in 2025 due to increased costs and decreased market prices [4] - Company Jieshun Technology (002609.SZ) projects a net profit of 55 million to 75 million yuan in 2025, representing a growth of 75.23% to 138.96% [4] - Company Lante Optics (688127.SH) expects a net profit of 375 million to 400 million yuan in 2025, a growth of 70.04% to 81.38% [5] - Company Duofuduo (002407.SZ) anticipates a net profit of 200 million to 280 million yuan in 2025, recovering from a loss of 30.8 million yuan in the previous year [5] - Company Efort (688165.SH) expects a net loss of 450 million to 550 million yuan in 2025, with losses expected to widen significantly [5] - Company Pulit (002324.SZ) forecasts a net profit of 361 million to 416 million yuan in 2025, a year-on-year increase of 155.76% to 194.73% [6] - Company Jinchun Co. (300877.SZ) expects a net profit of 82 million to 88 million yuan in 2025, a growth of 165.04% to 184.43% [6] - Company Huahai Pharmaceutical (600521.SH) anticipates a net profit of 224 million to 335 million yuan in 2025, a decline of 70% to 80% [6] Orders and Investments - Company Dinglong Co. (300054.SZ) plans to acquire 70% of Shenzhen Haofei New Materials Co. for 630 million yuan, with a total valuation of 900 million yuan [7] - Company Chuanhuan Technology (300547.SZ) intends to invest approximately 1.1 billion yuan to establish a manufacturing headquarters in Anhui [7] - Company Mongcao Ecological (300355.SZ) has terminated a PPP project agreement, with a total project cost of 83.87 million yuan [7] - Company Fengfan Co. (601700.SH) plans to acquire 51% of Beijing Yanling Jiaye Intelligent Technology Co. for 383 million yuan [8] - Company Haowei Group (603501.SH) intends to invest up to 50 million USD in AI chip supplier Aixin Yuanzhi [8] - Company Chengda Bio (688739.SH) plans to establish a wholly-owned subsidiary with an investment of 1 billion yuan focused on innovative drug development [8] - Company Chengda Bio (688739.SH) is also setting up a pharmaceutical investment fund with a total scale of up to 1 billion yuan [9] - Company Efort (688165.SH) is planning to acquire shares of Shanghai Shengpu Fluid Equipment Co. through a combination of cash and stock [9] Major Shareholder Changes - Company Tongfu Microelectronics (002156.SZ) reports that its controlling shareholder has reduced its stake by 15 million shares, decreasing its holding from 19.79% to 18.80% [10] Listing on Beijing Stock Exchange - Company Xiamen Tungsten (600549.SH) announces that its subsidiary Jinlong Rare Earth is applying for public stock issuance and listing on the Beijing Stock Exchange [11]

北京商报讯（记者 丁宁）1月26日晚间，华海药业（600521）发布2025年度业绩预告显示，预计2025年 归属净利润2.24亿元至3.35亿元，同比下降70%-80%。 华海药业表示，报告期内，国内制剂业务随着国内集采政策的扩面深化，价格持续承压，竞争进一步加 剧；同时，公司老产品存量市场竞争加剧，新产品上量尚需时间，进而导致国内制剂销售收入同比出现 下降，影响利润同比减少；原料药行业持续面临产能过剩与价格承压交织的激烈竞争，同时新产品因开 发周期长、受内外部经营环境变化因素影响大等特点，新项目产业化未达预期，共同影响原料药销售收 入同比出现下降，影响利润同比减少；此外，公司加快生物创新药研发项目的推进进度，相应研发投入 同比大幅增加。 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) expects a significant decrease in net profit for the fiscal year 2025, projecting a range between 224 million yuan and 335 million yuan, which represents a decline of approximately 70% to 80% compared to the previous year [1] Financial Performance - The company anticipates a reduction in net profit attributable to shareholders of approximately 78.398 million yuan to 89.498 million yuan compared to the same period last year [1]

Core Viewpoint - Huahai Pharmaceutical (600521) expects a significant decline in net profit attributable to shareholders for the fiscal year 2025, projecting a range between 224 million to 335 million yuan, representing a year-on-year decrease of 70% to 80% [1] Group 1: Financial Performance - The company anticipates a net profit decline due to intensified competition in the existing product market and the slow ramp-up of new products, leading to a decrease in domestic formulation sales revenue year-on-year [1] - The sales revenue of raw materials is also expected to decline year-on-year, impacted by the underperformance of new project industrialization [1] Group 2: R&D and Innovation - The company is accelerating the progress of its biopharmaceutical innovation projects, resulting in a significant year-on-year increase in R&D investment [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) expects a significant decline in net profit for the fiscal year 2025, with projections indicating a decrease of approximately 70% to 80% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 224 million and 335 million yuan [1] - The estimated net profit excluding non-recurring gains and losses is expected to be between 113 million and 226 million yuan, reflecting a decline of about 80% to 90% year-on-year [1] Business Challenges - Domestic formulation business faces pressure from expanded domestic centralized procurement policies, leading to intensified price competition and a decline in sales revenue [1] - The raw material pharmaceutical industry is experiencing severe competition due to overcapacity and price pressures, with new product development facing delays, resulting in decreased sales revenue [1] - Increased investment in the research and development of innovative biological drugs has led to a significant rise in R&D expenses [1] Non-Operating Gains - Non-operating gains increased by approximately 100 million to 130 million yuan, primarily due to fair value changes in financial assets and gains from the sale of partial equity [1]

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） 每经AI快讯，华海药业1月26日晚间发布业绩预告，公司2025年度实现归属于上市公司股东的净利润预 计在2.24亿元至3.35亿元之间，与上年同期相比，将减少约7.84亿元到约8.95亿元，同比降低约 70%~80%。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...